Veracyte, Inc. VCYT
50.32 USD +1.32 (+2.69%)
Nov 3, 2026, 3:37 PM EST
49.88 Day range 51.42
29.46 52-week range 60.91
- YTD
- +19.52%
- 1 year
- +38.05%
News
globenewswire.com Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026 Two oral presentations mark Afirma's strongest podium presence in recent years, alongside eight posters Two oral presentations mark Afirma's strongest podium presence in recent years, alongside eight…
globenewswire.com Veracyte to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will be participating in the following investor…
zacks.com Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
seekingalpha.com Artisan Mid Cap Fund Q3 2026 Portfolio Update The portfolio generated a negative absolute return but outpaced the Russell Midcap Growth Index. During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. We…
globenewswire.com Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO STAMPEDE study analysis providing new predictive evidence in…
zacks.com Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report? Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
defenseworld.net Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell? Veracyte, Inc. (NASDAQ: VCYT - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $45.25 and traded as low as…
globenewswire.com Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026 SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that six studies involving its genomic tests will…
benzinga.com Veracyte Announces Receiving Of Coverage For Its Prosigna Breast Risk Of Recurrence Test For Its Technical Assessment Submission Through Palmetto GBA’s MolDX Program Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Prosigna® Breast Risk of Recurrence (ROR) test has received coverage for its Technical Assessment…
globenewswire.com Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer Milestone supports broader U.S. adoption of Prosigna and expands access…
globenewswire.com Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026 SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the…
benzinga.com Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
benzinga.com Veracyte To Present New Findings From Retrospective Ancillary Analysis Of Randomized Phase III NRG/RTOG 0815 Trial At 2026 ASTRO Annual Meeting Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be…
globenewswire.com Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary…
globenewswire.com Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment…
zacks.com Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains? Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the…
defenseworld.net Veracyte (NASDAQ:VCYT) Insider John Leite Sells 4,015 Shares Veracyte, Inc. (NASDAQ: VCYT - Get Free Report) insider John Leite sold 4,015 shares of Veracyte stock in a transaction dated Monday, September 21st. The shares were sold at an average price of…
benzinga.com Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
defenseworld.net Squarepoint Ops LLC Sells 49,301 Shares of Veracyte, Inc. $VCYT Squarepoint Ops LLC decreased its holdings in Veracyte, Inc. (NASDAQ: VCYT) by 76.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional…
defenseworld.net Corient Private Wealth LP Has $9.52 Million Holdings in Veracyte, Inc. $VCYT Corient Private Wealth LP lifted its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 26.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange…
seekingalpha.com Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript- benzinga.com Veracyte Acquires Convergent Genomics In $150M Deal, With Up To $30M Milestone Payments Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its…
globenewswire.com Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey Acquisition positions Veracyte to…
defenseworld.net Concurrent Investment Advisors LLC Takes Position in Veracyte, Inc. $VCYT Concurrent Investment Advisors LLC bought a new position in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent filing with the SEC. The firm bought 17,644 shares of…
gurufocus.com Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investors On September 09, 2026, Veracyte Inc (VCYT) shares rose 3.3% to $43.85, reflecting a slight uptick amid a challenging price performance over the past month, whic
benzinga.com UBS Maintains Buy on Veracyte, Raises Price Target to $65 UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $52 to $65.
benzinga.com Top 3 Health Care Stocks That Could Blast Off This Month The health care sector's oversold stocks present buying opportunities for undervalued companies. RSI compares stock strength on up and down days, with an RSI below 30 considered oversold.
benzinga.com Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $54 Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $66 to $54.- benzinga.com Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $55 Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $68 to $55.
benzinga.com Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $44 Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $47 to $44.- benzinga.com Canaccord Genuity Maintains Hold on Veracyte, Lowers Price Target to $50 Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and lowers the price target from $60 to $50.
benzinga.com Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.- benzinga.com Needham Maintains Buy on Veracyte, Raises Price Target to $69 Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $57 to $69.
- benzinga.com Veracyte Raises FY2026 Sales Guidance from $582.000M-$592.000M to $590.000M-$596.000M vs $586.445M Est Veracyte (NASDAQ:VCYT) raises FY2026 sales outlook from $582.000 million-$592.000 million to $590.000 million-$596.000 million vs $586.445 million estimate.
benzinga.com This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and TNGX with positive ratings and price targets.
benzinga.com Piper Sandler Initiates Coverage On Veracyte with Overweight Rating, Announces Price Target of $66 Piper Sandler analyst David Westenberg initiates coverage on Veracyte (NASDAQ:VCYT) with a Overweight rating and announces Price Target of $66.
benzinga.com Canaccord Genuity Maintains Hold on Veracyte, Raises Price Target to $60 Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the price target from $42 to $60.- benzinga.com Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $47 Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raises the price target from $37 to $47.
- benzinga.com Guggenheim Maintains Buy on Veracyte, Raises Price Target to $65 Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $45 to $65.
benzinga.com Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,502 shares of Kodiak AI- benzinga.com Needham Maintains Buy on Veracyte, Raises Price Target to $57 Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $48 to $57.
benzinga.com Veracyte Commercially Rolls Out Prosigna Breast Risk Of Recurrence Test Across U.S. On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the U.S. commercial launch…- benzinga.com Veracyte To Present Results From Independent OPTIMA Trial, Led By University College London, At ASCO Annual Meeting Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node…
benzinga.com Canaccord Genuity Maintains Hold on Veracyte, Raises Price Target to $42 Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the price target from $40 to $42.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Davita, Bloomin' Brands, Compass And Other Big Stocks Moving Higher On Wednesday Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised guidance. Other gaining stocks include EVC, BLMN, MNKD, FLEX, HUT, AVTX, COMP, VCYT, and SSRM.
benzinga.com Full Transcript: Veracyte Q1 2026 Earnings Call - benzinga.com Veracyte Raises FY2026 Sales Guidance from $570.000M-$582.000M to $582.000M-$592.000M vs $576.521M Est Veracyte (NASDAQ:VCYT) raises FY2026 sales outlook from $570.000 million-$582.000 million to $582.000 million-$592.000 million vs $576.521 million estimate.
- benzinga.com Veracyte Q1 Adj. EPS $0.52 Beats $0.15 Estimate, Sales $139.071M Beat $130.041M Estimate Veracyte (NASDAQ:VCYT) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.15 by 246.67 percent. This is a 67.74 percent increase over earnings of $0.31 per…
benzinga.com Earnings Scheduled For May 5, 2026